Tag Archives: Israel

Christine Quinn at Technion City

Technion President Prof. Peretz Lavie with Christine Quinn of New York at Technion City, Feb. 2012.

“The Technion-Cornell Initiative will make our City the Global High-Tech Capital”

“The residents of New York City and its government are very excited about the planned applied science and engineering campus which Cornell and the Technion are partnering to establish”, said Christine Quinn, New York City council speaker, in her visit today to the Technion. “We have no doubt that this important venture, which will make our city the global high-tech capital, will inject new blood into it and improve all municipal aspects – from affordable housing to cafés and restaurants”.

Quinn, who in 2007 was ranked by the New York Post third in the list of the most influential women in New York, is a member of the Democratic Party, and is considered a leading candidate in the mayoral election that will end next year. She invests substantial resources in improving health care and in promoting affordable housing in New York. “We, as a municipality, cannot create entrepreneurial ventures, but we can and are committed to creating a suitable envelope for them: an efficient transportation system, personal security, housing, quality education and employment – without these, entrepreneurs and high-tech companies cannot be attracted to the city”.

 “Whenever I hear the slogan ‘Intel Inside’ I say: Haifa Inside.”

Technion President Professor Peretz Lavie said to the guest that the future is in the interdisciplinary realm, and that this is the rational behind the new campus that will be set-up  on Roosevelt Island in New York. “It may be that Prof. Shechtman is the last scientist to be awarded the Nobel Prize for research conducted by one person working alone in one laboratory,” said Prof. Lavie. “Nowadays, achieving significant scientific and engineering breakthroughs requires tremendous knowledge that the single scientist does not possess. In light of this, the new campus will be structured as interdisciplinary centers that will intercommunicate and overlap, rather than in the well-known university model of programs and faculties. With time this center will be surrounded by startup companies and extensions of large high-tech companies, just as such companies and extensions historically developed near the Technion. Intel is an example of a giant company that chose to establish here its first research center outside the US, and so whenever I hear the slogan ‘Intel Inside’ I say: Haifa Inside. Our innovative venture will build a bridge of friendship and cooperation between New York and Haifa”.

1912-2012: Technion Timeline of a Century.

Landmark behind Time





The Technion’s historic building was designed by the renowned Jewish German architect, Alexander Baerwald. His design includes both oriental and European motives. It is built from sandstone quarried in Tantura and Atlit. The building was part of Baerwald’s plan of an open corridor leading directly to the bay. He also designed buildings that would line the road, of which some were built, indeed (e.g. the Hebrew Reali School). 

The building’s cornerstone was laid in 1912. The building’s construction was delayed during the First World War. The partially completed building was used, then, as a military hospital. In 1925 it became the home of Israel’s first institute of higher education – The Technion, Israel Institute of Technology. Until 1953, all the Technion Faculties were located there. By 1965, most of them have moved to the Technion new campus in Haifa’s Nave Shaanan. The Faculty of Architecture and Town Planning stayed in the historic Technion building until 1985. 


Timeline of the Century

2012: Technion partners with Cornell University to found the Technion Cornell Institute of Innovation (TCII), an international ‘School of Genius’ in the heart of New York City.


2011: Technion Prof. Dan Shechtman receives the Nobel Prize in Chemistry for his discovery of quasicrystals.


2007: Technion pools its brainpower in a unique multidisciplinary center for research into energy science, technology and engineering: The Grand Technion Energy Program.


2006: Technion is Israel’s 1st university to receive the Nobel Prize for Science. Prof. Aaron Ciechanover and Prof. Avram Hershko jointly receive the Nobel Prize in Chemistry for their discovery, together with Irwin Rose, of the ubiquitin system within living cells.


2005: Technion opens the Russell Berrie Nanotechnology Institute (RBNI) to further empower and concentrate the plethora of excellent scientists, researchers and students pioneering science in the nano dimension.


2001: Technion scientists reveal they have long been quietly researching solutions to meet the threat of 3rd millennium terrorism as revealed by the horrific events in the US of September 11th


1998: Combining microbiology and microelectronics, scientists show how to make a transistor 1/100,000th the size of a human hair


1993: Technion students design and launch their own satellite: Gurwin Tech Sat. The satellite is still in orbit.


1991: Gulf War – Technion shows that the integration of expertise of Israel’s top institute of technology with its dynamic medical school makes Technion first responders in responding to missile attack on the home-front.


1989: Optoelectronics: A new center of excellence pioneering the technological promise of an expert understanding of light.


1982: The Rappaport Family Institute for Research in the Medical Sciences is established. During more than two decades of activity, the Institute has established itself as an internationally recognized research center and counts among its members several world-renowned scientists.
1981: Fiberoptics is pioneered by Technion


1978: Camp David accords with Egypt: the scientific challenges of peace and nation-planning means that in addition to its many projects in water management and environmental engineering, the Technion sets up the Samuel Neaman Institute.


1973: Yom Kippur War


1971: The Faculty of Biology is set up.


1969: The faculty of medicine is born. The first class consists of 43 students who had their preclinical education abroad. They were admitted to the fourth year and finished the requirements for the degree of Medical Doctor (M.D.), after two years of clinical training in the hospitals. The same year also sees the birth of the Department of Biomedical Engineering and the Faculty of Computer Science. 


1967: Six-Day War, Faculty of Materials Engineering is set up.


1966: Agricultural engineering degrees awarded to students from Africa and Asia


1965: Department of Education in Technology and Science


1962: Faculty of Food Engineering and Biotechnology 


1961: Technion offers a  flourishing graduate school and R&D foundation


1960: The Faculty of Mathematics and the Faculty of Physics are formed.

1958:  The opening of the Faculty of Chemistry, the Faculty of Industrial Engineering and Management, and The  Department of Humanities and Arts

1956: Students take part in the Sinai War


1954: Technion founding father Prof. Albert Einstein is awarded a Technion honorary doctorate. The Faculty of Chemical Engineering is opened.


1953:The Department of Aeronautical Engineering and the  Faculty of Agricultural Engineering are set up in the new campus.


1952: Rapid growth and expansion and increasing demand for Technion graduates and engineers nation-wide means the Technion leaves its first home in the historic building in down-town Haifa. Prime-Minister David Ben Gurion selects the new site for Technion City further up the slopes of Mount Carmel.


1948: With 680 students, Technion celebrates the declaration of independence. Studies are disrupted for most of the year as faculty and students fight for independence. The Faculty of Electrical Engineering and the Faculty of Mechanical Engineering are opened.


1944: Survival tasks – Technion develops early warning systems against air attacks as well as weapons for the Hagannah, the Israeli underground army that are preparing for the War of Independence.


1943: 1000 skilled Technion graduates join the war effort against Nazi Germany


1938: The Faculties of civil engineering, architecture, industrial engineering and opened, together with 11 new labs and a nautical school


1935: The Polish government recognizes Technion
1934: The Faculty of Industrial Technology is established covering broad fields. 


1931: Technion staff vote to work for nothing to ensure their institute survives.
1928: First class of 17 Technion engineers and architects graduates


1926: Zeev Jabotinsky addresses Technion Haganah members


1924: Technion officially enrolls 1st class of engineering students


1923: Einstein’s first visit in which he becomes president of the first Technion society, the German Technion Society




In 1923, Albert Einstein visited the empty building of the Technikum, where there was a plan to give courses for word workers, electricians and telephone and telegraph workers. Although the derelict buildings were being used as a hostel for immigrants from Europe, Albert Einstein did not think the dream of founding a technical university in the Middle East to be fantasy. As a great scientist, Einstein knew that what makes the impossible possible is the courage to follow an inspiration. 


1920: The building is legally acquired and recruitment for staff begins


1914: 1918 German, Turkish and then British troops occupy the building


1913: A battle continues over the language of Technion instruction: German or revitalized Hebrew?   Hebrew wins.


1912: The cornerstone is laid for Technion’s building


1908: Wissotzky, Schiff and the Jewish National Fund invest in the new “Technikum” 


1903: Hebrew teachers association of Palestine calls for a polytechnic university


1902 Herzl publishes the novel Altneuland  (The Old New Land), which takes place in Palestine, creating the vision for a Jewish state and Zionism.


1901: 5th Zionist congress calls for a Jewish technological university, as a first necessary step to realize the dream of a Jewish state.


File:Herzl.jpg


We began with a thought…
           
“Our technical inventors, who are the true benefactors of humanity… will discover things as marvelous as those we have already seen, or indeed more wonderful than these…”
Theordor Herzl, 1896, The Jewish State

In 1902, Theodor Herzl envisioned Haifa as “a great park….with an overhead electrical train…. a city of magnificent homes and public institutions all made possible by applied science, engineering and technology.” (Altneuland)
At that time, even an automobile was an exceptional extravagance of engineering. Electricity was still an expensive luxury for the elite few.
Haifa was a small, remote, coastal town most easily accessed by boat.
The advance of science and technology; the creation of the State of Israel; the emergence of the global village connected by the information superhighway; discoveries in basic science that have fundamentally changed the way scientists think about the material world, and the tremendous applied advances taking place in every corner of Technion City are just some of the miracles witnessed in the past century.

It all began with an inspirational thought in the mind of one man, Binyamin Ze’ev Herzl. Prof. Albert Einstein later added his mind to the vision. Thousands of great thinkers have since added to the blaze of light which is Technion, creating an institute of technology that in the 3rd millennium is truly a light to the nations.

1912-2012: Technion Timeline of a Century.

Landmark behind Time





The Technion’s historic building was designed by the renowned Jewish German architect, Alexander Baerwald. His design includes both oriental and European motives. It is built from sandstone quarried in Tantura and Atlit. The building was part of Baerwald’s plan of an open corridor leading directly to the bay. He also designed buildings that would line the road, of which some were built, indeed (e.g. the Hebrew Reali School). 

The building’s cornerstone was laid in 1912. The building’s construction was delayed during the First World War. The partially completed building was used, then, as a military hospital. In 1925 it became the home of Israel’s first institute of higher education – The Technion, Israel Institute of Technology. Until 1953, all the Technion Faculties were located there. By 1965, most of them have moved to the Technion new campus in Haifa’s Nave Shaanan. The Faculty of Architecture and Town Planning stayed in the historic Technion building until 1985. 


Timeline of the Century

2012: Technion partners with Cornell University to found the Technion Cornell Institute of Innovation (TCII), an international ‘School of Genius’ in the heart of New York City.


2011: Technion Prof. Dan Shechtman receives the Nobel Prize in Chemistry for his discovery of quasicrystals.


2007: Technion pools its brainpower in a unique multidisciplinary center for research into energy science, technology and engineering: The Grand Technion Energy Program.


2006: Technion is Israel’s 1st university to receive the Nobel Prize for Science. Prof. Aaron Ciechanover and Prof. Avram Hershko jointly receive the Nobel Prize in Chemistry for their discovery, together with Irwin Rose, of the ubiquitin system within living cells.


2005: Technion opens the Russell Berrie Nanotechnology Institute (RBNI) to further empower and concentrate the plethora of excellent scientists, researchers and students pioneering science in the nano dimension.


2001: Technion scientists reveal they have long been quietly researching solutions to meet the threat of 3rd millennium terrorism as revealed by the horrific events in the US of September 11th


1998: Combining microbiology and microelectronics, scientists show how to make a transistor 1/100,000th the size of a human hair


1993: Technion students design and launch their own satellite: Gurwin Tech Sat. The satellite is still in orbit.


1991: Gulf War – Technion shows that the integration of expertise of Israel’s top institute of technology with its dynamic medical school makes Technion first responders in responding to missile attack on the home-front.


1989: Optoelectronics: A new center of excellence pioneering the technological promise of an expert understanding of light.


1982: The Rappaport Family Institute for Research in the Medical Sciences is established. During more than two decades of activity, the Institute has established itself as an internationally recognized research center and counts among its members several world-renowned scientists.
1981: Fiberoptics is pioneered by Technion


1978: Camp David accords with Egypt: the scientific challenges of peace and nation-planning means that in addition to its many projects in water management and environmental engineering, the Technion sets up the Samuel Neaman Institute.


1973: Yom Kippur War


1971: The Faculty of Biology is set up.


1969: The faculty of medicine is born. The first class consists of 43 students who had their preclinical education abroad. They were admitted to the fourth year and finished the requirements for the degree of Medical Doctor (M.D.), after two years of clinical training in the hospitals. The same year also sees the birth of the Department of Biomedical Engineering and the Faculty of Computer Science. 


1967: Six-Day War, Faculty of Materials Engineering is set up.


1966: Agricultural engineering degrees awarded to students from Africa and Asia


1965: Department of Education in Technology and Science


1962: Faculty of Food Engineering and Biotechnology 


1961: Technion offers a  flourishing graduate school and R&D foundation


1960: The Faculty of Mathematics and the Faculty of Physics are formed.

1958:  The opening of the Faculty of Chemistry, the Faculty of Industrial Engineering and Management, and The  Department of Humanities and Arts

1956: Students take part in the Sinai War


1954: Technion founding father Prof. Albert Einstein is awarded a Technion honorary doctorate. The Faculty of Chemical Engineering is opened.


1953:The Department of Aeronautical Engineering and the  Faculty of Agricultural Engineering are set up in the new campus.


1952: Rapid growth and expansion and increasing demand for Technion graduates and engineers nation-wide means the Technion leaves its first home in the historic building in down-town Haifa. Prime-Minister David Ben Gurion selects the new site for Technion City further up the slopes of Mount Carmel.


1948: With 680 students, Technion celebrates the declaration of independence. Studies are disrupted for most of the year as faculty and students fight for independence. The Faculty of Electrical Engineering and the Faculty of Mechanical Engineering are opened.


1944: Survival tasks – Technion develops early warning systems against air attacks as well as weapons for the Hagannah, the Israeli underground army that are preparing for the War of Independence.


1943: 1000 skilled Technion graduates join the war effort against Nazi Germany


1938: The Faculties of civil engineering, architecture, industrial engineering and opened, together with 11 new labs and a nautical school


1935: The Polish government recognizes Technion
1934: The Faculty of Industrial Technology is established covering broad fields. 


1931: Technion staff vote to work for nothing to ensure their institute survives.
1928: First class of 17 Technion engineers and architects graduates


1926: Zeev Jabotinsky addresses Technion Haganah members


1924: Technion officially enrolls 1st class of engineering students


1923: Einstein’s first visit in which he becomes president of the first Technion society, the German Technion Society




In 1923, Albert Einstein visited the empty building of the Technikum, where there was a plan to give courses for word workers, electricians and telephone and telegraph workers. Although the derelict buildings were being used as a hostel for immigrants from Europe, Albert Einstein did not think the dream of founding a technical university in the Middle East to be fantasy. As a great scientist, Einstein knew that what makes the impossible possible is the courage to follow an inspiration. 


1920: The building is legally acquired and recruitment for staff begins


1914: 1918 German, Turkish and then British troops occupy the building


1913: A battle continues over the language of Technion instruction: German or revitalized Hebrew?   Hebrew wins.


1912: The cornerstone is laid for Technion’s building


1908: Wissotzky, Schiff and the Jewish National Fund invest in the new “Technikum” 


1903: Hebrew teachers association of Palestine calls for a polytechnic university


1902 Herzl publishes the novel Altneuland  (The Old New Land), which takes place in Palestine, creating the vision for a Jewish state and Zionism.


1901: 5th Zionist congress calls for a Jewish technological university, as a first necessary step to realize the dream of a Jewish state.


File:Herzl.jpg


We began with a thought…
           
“Our technical inventors, who are the true benefactors of humanity… will discover things as marvelous as those we have already seen, or indeed more wonderful than these…”
Theordor Herzl, 1896, The Jewish State

In 1902, Theodor Herzl envisioned Haifa as “a great park….with an overhead electrical train…. a city of magnificent homes and public institutions all made possible by applied science, engineering and technology.” (Altneuland)
At that time, even an automobile was an exceptional extravagance of engineering. Electricity was still an expensive luxury for the elite few.
Haifa was a small, remote, coastal town most easily accessed by boat.
The advance of science and technology; the creation of the State of Israel; the emergence of the global village connected by the information superhighway; discoveries in basic science that have fundamentally changed the way scientists think about the material world, and the tremendous applied advances taking place in every corner of Technion City are just some of the miracles witnessed in the past century.

It all began with an inspirational thought in the mind of one man, Binyamin Ze’ev Herzl. Prof. Albert Einstein later added his mind to the vision. Thousands of great thinkers have since added to the blaze of light which is Technion, creating an institute of technology that in the 3rd millennium is truly a light to the nations.

Keep it PURE – Nano filters for cleantech & desalination.

Handing you the Future ~
1912-2012: the Technion Centennial Stamp features
one application of the innovative nano fibers
Featured on the Technion 2012 Cornerstone Centennial Stamp, the nanofibers behind the dynamic new start-up NanoSpun signify many of the secrets of Technion’s success in conceptualizing, shaping and nurturing Israel as the high-tech global success of the third millennium.
 
Why would Cornell University and New York City invite Technion to set up a new campus on Roosevelt Island, in order to boost economic growth through innovation and entrepreneurship? Throughout the world, news headlines have cited Technion’s unique ability to produce dynamic and profitable start ups using advanced technology and skills. In 2012, one company that exemplifies the secrets of this success is the prize-winning start up NanoSpun.

National Stamp Marks 100 years of Technion

Israeli post gets smart with the Technion Centennial Stamp

The Israel Postal Company’s Philatelic Service is issuing a stamp celebrating the 100th anniversary of the cornerstone laying ceremony in Haifa of the Technion.


The new stamp will be unveiled as part of the Technion’s centennial activities, which will be launched on Tuesday President, Prof. Peretz Lavie, Haifa Mayor Yona Yahav and the postal authorities. 


The stamp shows a sketch of the old Technion building’s plans and the image of a nano parachute developed at the Technion at the lab of Prof. Eyal Zussman.  The Nanofiber technology recently led to the establishment of a prize-winning new company, NanoSpun through the T3 Technion Technology Transfer office. 


The Technion was Israel’s first academic institution and is today one of the most prominent in its field, Postal Company board chairman Sasii Shilo told the Jerusalem Post.


Ubiquitin gets ubiquitous through the post… Technion’s first Nobel Laureates in Chemistry were also honored last year by a stamp released to celebrate their discovery. Read the full story here.

National Stamp Marks 100 years of Technion

Israeli post gets smart with the Technion Centennial Stamp

The Israel Postal Company’s Philatelic Service is issuing a stamp celebrating the 100th anniversary of the cornerstone laying ceremony in Haifa of the Technion.


The new stamp will be unveiled as part of the Technion’s centennial activities, which will be launched on Tuesday President, Prof. Peretz Lavie, Haifa Mayor Yona Yahav and the postal authorities. 


The stamp shows a sketch of the old Technion building’s plans and the image of a nano parachute developed at the Technion at the lab of Prof. Eyal Zussman.  The Nanofiber technology recently led to the establishment of a prize-winning new company, NanoSpun through the T3 Technion Technology Transfer office. 


The Technion was Israel’s first academic institution and is today one of the most prominent in its field, Postal Company board chairman Sasii Shilo told the Jerusalem Post.


Ubiquitin gets ubiquitous through the post… Technion’s first Nobel Laureates in Chemistry were also honored last year by a stamp released to celebrate their discovery. Read the full story here.

NANO Nutraceuticals – pioneering health.

Nanocapsules developed by Technion researchers from natural materials can also be used by the pharmaceutical industry – in the protection of medicines in the stomach and their release in the intestine, as well as for targeting cancerous tumors

Image Detail
Technion researchers have created nanocapsules that are based on natural food components, and trapped in them vitamins and nutraceuticals (health-enhancing micronutrients) that do not dissolve well in water. The nanocapsules can be added to clear beverages, thus increasing their health benefits without clouding them.
Dr. Yoav Livney and his team in the Faculty of Biotechnology and Food Engineering used the Maillard reaction to create nanocapsules based on the protein–polysaccharide conjugates. This natural reaction, which is the cause of the browning of food during baking and cooking, was used in the past in the creation of emulsions and microcapsules for nutrients that do not dissolve in water, but the problem with the existing methods is that the capsules obtained were large, so that they clouded the liquid they were added to.
To overcome this problem, Dr. Livney and his team conjugated maltodextrin, a product of the breakdown of starch into Casein, milk protein, in a controlled process. The conjugated molecules (conjugates) underwent spontaneous self-assembly into capsules of nanometric dimensions. These nanocapsules are so small, that the beverages they were added to remained clear.
In the next stage, the researchers trapped in the nanocapsules vitamin D (large parts of the population suffer from vitamin D deficiency, which could cause rickets in children and many other health disorders in adults). The research team found that the nanocapsules protect the vitamins “packed” in them. “They protected the vitamin D from degrading in an acidic environment, and during its refrigerated shelf-life”, says Dr. Livney. 
Another important material called EGCG (epigallocatechin gallate), that is found in green tea and that is considered to inhibit many diseases, among them are neurodegenerative diseases, cardiovascular diseases and cancer, was also significantly protected by the conjugates throughout its shelf-life.
The researchers also followed the release of the nutrients from the nanocapsules under simulated digestion conditions. They discovered that the nanocapsules succeeded in keeping the nutrients trapped in them, and in protecting them under stomach conditions. Livney believes that the enzymes in the small intestine will break the polysaccharide-protein envelope down easily, allowing the absorption of the nutritional nano-cargo at the desired location, in the small intestine.

In the future, Dr. Livney plans to “research the overall release profile of nutraceuticals through simulated digestion, and later to examine their bioavailability in vivo in clinical trials”. He adds that “we also intend to investigate the encapsulation by this method of other bio-active components, such as anti-cancer medicines.
Another team headed by Dr. Livney is currently developing the next generation of polysaccharide-protein conjugate-based nanocapsules, which are aimed at target-oriented delivery of medicines in the body, marking the location of cancerous tumors and destroying them.

Prior to becoming a faculty member in the Technion’s Faculty of Biotechnology and Food Engineering, Yoav Livney was involved in the development of “Gamadim”, “Ski” and “Symphony”, as part of his work as the product development manager of the cheese business unit at “Strauss”.

Nobel Prize Winning Ubiquitin in Action

Proteologics’ pioneers targeted drug development CEO Joshua Levin discusses the molecules being developed with Teva and GlaxoSmithKline.[Extracted from Globes, Israel]

The award of the 2011 Nobel Prize in Chemistry to Prof. Dan Schechtman, following the 2009 win by Prof. Ada Yonath, put the world of chemistry and Israel’s contributions to science that laypeople can barely understand in the limelight. Schechtman and Yonath have not yet turned their discoveries, of quasi-crystals and the mechanism of the ribosome, respectively, into commercial products, but their two Israeli predecessors, Prof. Aaron Ciechanover and Prof. Avram Hershko, the 2004 Nobel Laureates in Chemistry, have succeeded in doing so (or at least trying). They contributed their know-how and reputations to Proteologics Ltd. (TASE: PRTL).

Ubiquitin – the new buzzword

To understand what Proteologics is doing, it is necessary to go back to high school chemistry and the stubborn teacher who tried to explain what a protein is. The company is developing targeted therapeutics for the ubiquitin system, which regulates almost all aspects of eukaryotic cellular function, including cell cycle regulation, DNA repair, signal transduction, immune response, protein quality control and metabolism. The system comprises about 1,000 protiens.
Hershko and Ciechanover discovered the ubiquitin system in 1978, and jointly won the Nobel Prize in Chemistry in 2004 for the discovery. They are both members of Proteologics’ science advisory board.
Targeted medications are not regular drugs; as their name implies, they have just one specific target, and are consequently more effective, (improving a patient’s quality of life by reducing the side effects of treatment) and are more efficient for health funds by cutting costs. These drugs discover the proteins that play an important role in a disease, neutralizing which leads to improvement, even a cure, for the disease in question.
A ubiquitin is a small regulatory protein that can be attached to proteins and label them for destruction for the proper function of the cell. Ubiquitin tags can also direct proteins to other locations in the cell, where they control other protein and cell mechanisms. Disruption of the ubiquitin system is therefore liable to cause a wide range of diseases, including cancers, diseases of the nervous system such as Alzheimer’s or Parkinson’s, muscular dystrophy, and viral diseases.
Drug development is complicated, and the difficulties are compounded in the case of the ubiquitin system. It is a hierarchal cascade system with three levels: The E1 enzyme is a single protein, which can bind with the subordinate level, E2 enzymes (of which there are about 40), which in turn influence the more than 600 E3 enzymes.
This hierarchal cascade and the multiple E2-E3 connections complicates the drug development task. E3 enzymes directly transfer the signal to the protein, and this is where Proteologics finds the proteins that are the basis for its therapeutics. Any intervention higher up in the hierarchy is liable to cause harm rather than help.
Business model: spread the risk
Proteologics’ business model may prove in future to be much more effective than the models of other R&D companies. The drug development and approval process has three main stages. First is identification of the target and development of a suitable molecule, which is followed by preclinical and human clinical trials.
Proteologics only operates at the first and second stages, while the final stage, which requires more time and financial investment, is handled by the company’s big pharma partners – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and GlaxoSmithKline plc (NYSE; LSE: GSK).
In this way, Proteologics reduces its financial risk, as the clinical trial and most expensive stage is carried out by big pharma companies which bear the financial risk. Proteologics even receives advances for R&D costs, which are partly covered by its partners. The company also has an option for receiving milestone payments, and will receive generous royalties from sales, assuming that the drug is approved for marketing.
Until that day comes, if it ever does, Proteologics can use the milestone payments to pursue additional projects on the basis of the platform it developed for working with E3 enzymes with different tags. This enables the company to survive, in theory, for a long time as it expands its knowledge and its platform to create a large enough product base that will increase its chances of turning at least one of its drug candidates into a commercial product.
Proteologics CEO Joshua Levin says that it has been able to lower its risk profile by choosing two partners that complements each other, in both character and terms of the agreements signed with them. GlaxoSmithKline, a UK giant with a market cap of $117 billion, is developing with Proteologics six programs for the treatment of various cancers (each program is based on a different E3 enzyme). Teva is jointly developing three programs. Proteologics is also developing two programs independently, and will either continue to do so or find a partner.
“GlaxoSmithKline and Teva complement each other,” says Levin. “Teva is not an innovative company, which is why it chose to invest a little in us now, and give us a larger share of revenue from drug sales. GlaxoSmithKline, in contrast, chose to invest much more in us at the first and second stages, and took a greater share for itself when the drug reaches market.”
In the case of GlaxoSmithKline, which is the more important partner for Levin, each program could generate up to $176 million in royalties, or up to $1 billion altogether, but Levin is realistic about these numbers. “This isn’t a real number. There’s no chance that all six drugs will be commercialized,” he says.

2012 is the critical year

Under Proteologics’ timetable, 2012 will be a critical year. Teva, which has undergone quite a few changes, mainly as a result of its acquisition of Cephalon, is scheduled to receive its first molecule from Proteologics within months, and will have to decide whether it wants to pursue development. If it chooses not to do so, Proteologics can continue development (a Phase I clinical trial) independently, or find another partner, without the need to start the development process from scratch.
Levin is not worried that either Teva or GlaxoSmithKline will return molecules to the company, but he is nonetheless doing everything to make sure that does not happen. In the case of GlaxoSmithKline, each program has a three-year timeframe, which means that in early 2013, Proteologics will have to hand over the first molecule to it and wait for a response.
Read full article at Globes

Nobel Prize Winning Ubiquitin in Action

Proteologics’ pioneers targeted drug development CEO Joshua Levin discusses the molecules being developed with Teva and GlaxoSmithKline.[Extracted from Globes, Israel]

The award of the 2011 Nobel Prize in Chemistry to Prof. Dan Schechtman, following the 2009 win by Prof. Ada Yonath, put the world of chemistry and Israel’s contributions to science that laypeople can barely understand in the limelight. Schechtman and Yonath have not yet turned their discoveries, of quasi-crystals and the mechanism of the ribosome, respectively, into commercial products, but their two Israeli predecessors, Prof. Aaron Ciechanover and Prof. Avram Hershko, the 2004 Nobel Laureates in Chemistry, have succeeded in doing so (or at least trying). They contributed their know-how and reputations to Proteologics Ltd. (TASE: PRTL).

Ubiquitin – the new buzzword

To understand what Proteologics is doing, it is necessary to go back to high school chemistry and the stubborn teacher who tried to explain what a protein is. The company is developing targeted therapeutics for the ubiquitin system, which regulates almost all aspects of eukaryotic cellular function, including cell cycle regulation, DNA repair, signal transduction, immune response, protein quality control and metabolism. The system comprises about 1,000 protiens.
Hershko and Ciechanover discovered the ubiquitin system in 1978, and jointly won the Nobel Prize in Chemistry in 2004 for the discovery. They are both members of Proteologics’ science advisory board.
Targeted medications are not regular drugs; as their name implies, they have just one specific target, and are consequently more effective, (improving a patient’s quality of life by reducing the side effects of treatment) and are more efficient for health funds by cutting costs. These drugs discover the proteins that play an important role in a disease, neutralizing which leads to improvement, even a cure, for the disease in question.
A ubiquitin is a small regulatory protein that can be attached to proteins and label them for destruction for the proper function of the cell. Ubiquitin tags can also direct proteins to other locations in the cell, where they control other protein and cell mechanisms. Disruption of the ubiquitin system is therefore liable to cause a wide range of diseases, including cancers, diseases of the nervous system such as Alzheimer’s or Parkinson’s, muscular dystrophy, and viral diseases.
Drug development is complicated, and the difficulties are compounded in the case of the ubiquitin system. It is a hierarchal cascade system with three levels: The E1 enzyme is a single protein, which can bind with the subordinate level, E2 enzymes (of which there are about 40), which in turn influence the more than 600 E3 enzymes.
This hierarchal cascade and the multiple E2-E3 connections complicates the drug development task. E3 enzymes directly transfer the signal to the protein, and this is where Proteologics finds the proteins that are the basis for its therapeutics. Any intervention higher up in the hierarchy is liable to cause harm rather than help.
Business model: spread the risk
Proteologics’ business model may prove in future to be much more effective than the models of other R&D companies. The drug development and approval process has three main stages. First is identification of the target and development of a suitable molecule, which is followed by preclinical and human clinical trials.
Proteologics only operates at the first and second stages, while the final stage, which requires more time and financial investment, is handled by the company’s big pharma partners – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and GlaxoSmithKline plc (NYSE; LSE: GSK).
In this way, Proteologics reduces its financial risk, as the clinical trial and most expensive stage is carried out by big pharma companies which bear the financial risk. Proteologics even receives advances for R&D costs, which are partly covered by its partners. The company also has an option for receiving milestone payments, and will receive generous royalties from sales, assuming that the drug is approved for marketing.
Until that day comes, if it ever does, Proteologics can use the milestone payments to pursue additional projects on the basis of the platform it developed for working with E3 enzymes with different tags. This enables the company to survive, in theory, for a long time as it expands its knowledge and its platform to create a large enough product base that will increase its chances of turning at least one of its drug candidates into a commercial product.
Proteologics CEO Joshua Levin says that it has been able to lower its risk profile by choosing two partners that complements each other, in both character and terms of the agreements signed with them. GlaxoSmithKline, a UK giant with a market cap of $117 billion, is developing with Proteologics six programs for the treatment of various cancers (each program is based on a different E3 enzyme). Teva is jointly developing three programs. Proteologics is also developing two programs independently, and will either continue to do so or find a partner.
“GlaxoSmithKline and Teva complement each other,” says Levin. “Teva is not an innovative company, which is why it chose to invest a little in us now, and give us a larger share of revenue from drug sales. GlaxoSmithKline, in contrast, chose to invest much more in us at the first and second stages, and took a greater share for itself when the drug reaches market.”
In the case of GlaxoSmithKline, which is the more important partner for Levin, each program could generate up to $176 million in royalties, or up to $1 billion altogether, but Levin is realistic about these numbers. “This isn’t a real number. There’s no chance that all six drugs will be commercialized,” he says.

2012 is the critical year

Under Proteologics’ timetable, 2012 will be a critical year. Teva, which has undergone quite a few changes, mainly as a result of its acquisition of Cephalon, is scheduled to receive its first molecule from Proteologics within months, and will have to decide whether it wants to pursue development. If it chooses not to do so, Proteologics can continue development (a Phase I clinical trial) independently, or find another partner, without the need to start the development process from scratch.
Levin is not worried that either Teva or GlaxoSmithKline will return molecules to the company, but he is nonetheless doing everything to make sure that does not happen. In the case of GlaxoSmithKline, each program has a three-year timeframe, which means that in early 2013, Proteologics will have to hand over the first molecule to it and wait for a response.
Read full article at Globes

How start-ups get started. Israel, NYC & TCII

Silicon Island: a NYC hub for technology transfer

“We are glad to have the opportunity to join forces with Cornell University, to tap into the already rich innovative New York based eco-system and share our tech-transfer practices, insights and methodologies”

One of the most significant global academic milestones of this century must be the decision announced on December 19th 2011 by New York Mayor Bloomberg of Cornell University and Technion-Israel Institute of Technology as winners in a $2 billion competition to build a science and engineering campus on Roosevelt Island. The planned campus aims to serve 2,500 students and 280 faculty by 2043. It also intends to boost the number of graduate engineering students in the area by 70 percent. For the first time in history, the new academic venture will be called an institute of “Innovation”.

For Technion scientists patenting new technologies and looking at commercialization, TCII represents a foothold in New York City which is vital for global commercialization and networking. US investors will also have a domestic gateway to emerging technologies from Israel’s top powerhouse of innovation.

Included in plans for TCII (the Technion Cornell Institute of Innovation), is a $150 million fund to spawn New York area startups. The move comes on the heels of plans from IBM, Intel and others to participate in a $4.4 billion New York state effort to develop semiconductor technology for 450mm wafers.

“The message we are sending with this announcement is: look out Silicon Valley, look out Boston, New York will be second to none,” stated U.S. Senator Charles E. Schumer.

The campus will be organized around three interdisciplinary hubs: Connective Media, Healthier Life, and the Built Environment. Cornell will immediately offer Master and Doctoral degrees in areas such as Computer Science, Electrical and Computer Engineering, and Information Science and Engineering. In addition, after receiving the required accreditation, the campus will also offer innovative Technion-Cornell dual Master of Applied Sciences degrees. The concept of organizing TCII into multidiciplinary ‘hubs’ was introduced by the Technion, based on its successful multidisciplinary research centers, such as the Grand Technion Energy Program, says Technion President Peretz Lavie.

The TCII Campus will host entrepreneurs-in-residence, organize business competitions, provide legal support for startups, reach out to existing companies to form research partnerships and sponsor research, and establish a pre-seed financing program to support promising research. In addition, the campus will structure its tech transfer office, which will be on-site, to facilitate startup formation and technology licensing. The TCII Campus will also establish a $150 million revolving financing fund that will be solely devoted to start-up businesses in new York City.

“Starting today, we are going to put our plan to work, tapping into our extensive connections throughout the city and build a truly 21st Century campus to fuel the creation of new businesses and new industries throughout the city for decades to come.

“Technology Transfer activity takes place at the Technion in many shapes and forms resulting in significant economic development both locally and nationally,” says manager of the Technion Technology Transfer Office ( T3 ) Benjamin Soffer. “We are glad to have the opportunity to join forces with Cornell University, tap into the already rich innovative New York based eco-system and share our tech-transfer practices, insights  and methodologies to the benefit of the state of New York and the US at large.” 

IP (intellectual property) coming out of the TCII will be held jointly by Cornell University and Technion.

According to Israel’s Ministry of Foreign Affairs, Technion has a world-class track-record in research, development and entrepreneurship. The Technion’s departments of Electrical Engineering and Computer Science are considered among the best in the world. It  boasts top ranking faculty members including Nobel laureates. The Technion has long been considered a driving force behind Israel’s emergence as one of the world’s great centers of technology.

“Israel’s heros used to be the generals; now, the heros are the entrepreneurs.”

Technion  T3 Manager Benjamin Soffer,

Israel today has one of the highest concentrations of high-tech start-up companies globally. In partnership with a strong community of incubators, private investors, venture capitalists, angel groups and entrepreneurs, the Technion’s tech transfer arm, Technion Technology Transfer ( T3 ), has filed an average of 300 new patents each year and annually nurtures innovative startups in sectors such as clean-tech, cell therapy, drug delivery, nanotechnology and others. Companies including Intel, Google, Microsoft, IBM, Qualcomm, Broadcom, Yahoo! and Hewlett-Packard have established major operations near or on the Technion campus. Only this month, Apple announced that it will be joining the others to set up a ground-breaking R&D Center near Technion City – to be headed by Technion graduate Aharon Aharon.

Technion graduates currently head nearly half of the 121 Israeli companies on the NASDAQ, which have a combined market value of over $28 billion. More than 70 percent of the Technion graduates are employed in the high technology sectors that drive Israel’s economic growth.  Presently, Israeli companies headed by the Technion graduates employ 85 percent of Israel’s technical workforce.  According to a recent article in the Israeli newspaper Haaretz, there are approximately 4,000 start-up companies located around the Technion’s home campus.

President Lavie addresses press. NYC, 19th December, 2011

With the selection of Cornell/Technion now complete, the project is scheduled to move into the environmental and land use review process, expected to be completed by the fall of 2013. Groundbreaking on the first phase of the Roosevelt Island campus is expected by the beginning of 2015. A temporary off-site campus will be open in 2012.